Download Free Medical Adverse Events Unanticipated Problems and Protocol Deviations PowerPoint Presentation

Adverse Events Unanticipated Problems and Protocol Deviations PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical presentation on Adverse Drug Events, which is titled "Adverse Events, Unanticipated Problems, and Protocol Deviations", to know about the importance of adverse event reporting to clinical investigation and patient safety.

Tags : Adverse Drug Events, Adverse Events, Protocol Deviations, patient safety

Published on : Jul 20, 2021 | Views : 1997 | Downloads : 0

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Adverse Events, Unanticipated Problems, and Protocol DeviationsKathleen O’Malley RN, BSN, CCRPManager of Education and TrainingJefferson Clinical Research InstituteKathleen.omalley@jefferson.edu 1
Slide 2-

Learning Objectives: Adverse Events Understand the importance of adverse event reporting to clinical investigation and patient safety Define and identify adverse events (AEs) Define and identify serious adverse events (SAEs) Define unanticipated problems (UAPs) Understand Investigator, Clinical Research Coordinator (CRC) and Sponsor responsibilities with regards to identifying, documenting and reporting AEs 2
Slide 3-

Why do we collect Adverse Event data? To determine the safety profile of a drug or device To evaluate the risks and benefits of a product To provide information for the package insert, if approved for marketing Determination of safety is often one of the primary protocol objectives when evaluating new therapies Lui and Davis, 2013 3
Slide 4-

Protecting subject safety is one of the most important responsibilities of an investigator Federal mandate (21CFR 312.64) = the law! and commitment (FDA form 1572) 4
Slide 5-

Institutional Review Boards (IRBs) also share the responsibility Ensure studies do not expose subjects to undue harm Ensure the risk-benefit ratio falls within an acceptable range 45CFR 46.103(b)(5) and 21CFR 56.108 (b)(1) 5
Slide 6-

Adverse Event Definition: any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related 21 CFR 312.32 (a) Unanticipated Adverse Device Effect: any serious adverse effect on health or safety or any life-threatening problem or death caused by or associated with a device, if not identified in the device brochure, protocol, or consent form 21 CFR 812.3(s) 6
Slide 7-

Synonyms of Adverse “Event” include: Effect Experience Health consequence Occurrence Outcome Reaction (to a drug) Goldfarb, 2012, pg. 3,15 7
Slide 8-

Examples of AEs: Abnormal lab value Worsening of pre-existing condition Physical sign or symptom Abnormal exam, test or procedure result Concurrent illness Subjective report Change in vital signs or physical exam 8
Slide 9-

Examples of AEs: Complication from surgery or procedure Psychological symptoms or harm Device malfunction/failure Device user error Incorrect dose or overdose Drug dependence *Important to know the subject’s baseline conditions and concomitant medications (time of enrollment)! 9
Slide 10-

Examples of what AEs are not: A procedure or surgery The medical condition that caused the need for the procedure or surgery is the AE Pre-existing condition that remains unchanged during the study **A thorough history and physical at baseline is a must, to discern what is and is not an AE 10
Slide 11-

Serious Adverse Event definition (SAE): An adverse event or suspected adverse reaction is considered "serious" if, in the view of either the investigator or sponsor, it results in any of the following outcomes: Death Life-threatening adverse event Inpatient hospitalization or prolongation of existing hospitalization Persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions Congenital anomaly/birth defect Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered serious when, based upon appropriate medical judgment, they may jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition 21 CFR 312.32 11
Slide 12-

Where are you going to identify AEs? Medical Records Lab reports, radiology reports, progress notes, surgical reports Subject questionnaires Subject diaries Medication reconciliation 12
Slide 13-

Where are you going to identify AEs? Observation Specific information for Case Report Forms (CRFs) Open ended questions to subject and family “How have you been feeling since I saw you last?” “Can you describe any changes since you started the study medication?” 13
Slide 14-

How are you going to identify AEs? Develop a systematic method for collecting information Use tools to ensure thoroughness Practice open ended questions Avoid leading questions: “Are you experiencing nausea?” Remain objective Take time to reassure the patient and listen 14
Slide 15-

Documenting AEs: 15
Slide 16-

Documenting AEs: Event (nomenclature/description) Grading (Severity/Intensity) Relationship (Causality) Expected? Serious? Action taken (Treatment?) Duration Outcome 16
Slide 17-

Event: Terminology used to describe event is very important “Preferred terms” often defined in the protocol or by the sponsor Inaccurate or inconsistent coding of events may lead to missed safety signals Examples: Wheezing vs. Bronchospasm vs. Asthma Hypertension vs. high blood pressure A coding dictionary may be used: MedDRA (Medical Dictionary for Regulatory Activities) 17
Slide 18-

Event: Understanding documentation requirements in advance prevents queries, additional work and possible erroneous data 18
Slide 19-

Grading (Severity): Common Terminology Criteria for Adverse Events (CTCAE) created by the Health and Human Services, National Institutes of Health, National Cancer Institute http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf 19
Slide 20-

Grading (Severity): Grade 1 Mild: asymptomatic or mild symptoms; intervention not indicated Grade 2 Moderate: minimal intervention indicated; may limit ADLs Grade 3 Severe: medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL Grade 4 Life-threatening: consequences; urgent intervention indicated Grade 5 Death: related to AE http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf 20
Slide 21-

Severe Serious! *Severity refers to the intensity of an event *Seriousness is a guide for defining regulatory reporting obligations based on patient/event outcome or action usually associated with events that threaten a patient's life or functioning 21
Slide 22-

Severe Serious! Example: New onset migraine; lasting two days, causing subject to stay in bed and miss work, unable to care for children Not life threatening, No hospitalization, No persistent disability, Not Serious But, intensity is Severe 22
Slide 23-

Relationship (Causality): Is there a reasonable possibility that the event was related to, or caused by the investigational intervention? 23 **Relationship terms and descriptions are often defined in the protocol, by the sponsor
Slide 24-

Relationship (Causality): 24
Slide 25-

Expected versus Unexpected: Expected AEs will be described in the following: Investigator’s Brochure (IB); contains information regarding all AEs reported in all trials of the test article, to date Package Insert; safety and dosing information on all approved products Protocol and Informed Consent Safety profile of other drugs in the same class 25
Slide 26-

Expected versus Unexpected: Unexpected adverse event: not listed in the investigator brochure or is not listed at the specificity or severity that has been observed (or, if an investigator brochure is not required or available) not consistent with the risk information described in the general investigational plan 21 CFR 312.32 (a) ** There are often specific and/or expedited timelines and reporting requirements for Unexpected AEs -Know your Institutional and Sponsor requirements 26
Slide 27-

Expected versus Unexpected: Examples: if the investigator brochure referred only to elevated hepatic enzymes or hepatitis hepatic necrosis would be unexpected (by virtue of greater severity). if the investigator brochure listed only cerebral vascular accidents cerebral thromboembolism and cerebral vasculitis would be unexpected (by virtue of greater specificity). 27
Slide 28-

Serious?: Death a life-threatening adverse event inpatient hospitalization or prolongation of existing hospitalization a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions a congenital anomaly/birth defect Important medical events ** There are often specific and/or expedited timelines and reporting requirements for SAEs -Know your Institutional and Sponsor requirements 28
Slide 29-

Action Taken(treatment): 29 Specific information collected defined in protocol by sponsor Often, all treatments will need to be documented in the CRF or follow-up reports
Slide 30-

Duration and Outcome: Duration: Start and Stop date (and sometimes time) this may be unknown or ongoing Outcome: Resolved Ongoing Resolved with sequelae 30
Slide 31-

Reporting AEs: All about safety! 31
Slide 32-

Reporting Responsibility: Investigators and IRBs must promptly report information regarding AEs or unanticipated problems that involve risks to subjects or others 21 CFR 312.53 (c)(1)(vii), 21 CFR 56.108 (b)(1) 32
Slide 33-

Reporting Responsibility: *All AEs should be reviewed by and signed by a qualified clinician/investigator **Know the reporting requirements and timelines for your institution and study! 33
Slide 34-

ppt slide no 34 content not found
Slide 35-

Expected versus Unexpected: Expected AEs will be described in the following: Investigator’s Brochure (IB); contains information regarding all AEs reported in all trials of the test article, to date Package Insert; safety and dosing information on all approved products Protocol and Informed Consent Safety profile of other drugs in the same class 35
Slide 36-

Reporting Guidelines: Quorum Review IRB **Must meet all three criteria Serious Unanticipated Related – “a reasonable possibility that the adverse event may have been caused by the study product or study procedures (e.g. possibly, probably and definitely related”) **Must be reported within 10 business days 36
Slide 37-

Internal versus External AEs In the context of a multi-center trial Internal AE is an event that is experienced by subjects enrolled at your institution Also known as On-Site External AE in an event experienced by subjects enrolled at other institutions that are participating in the same multi-center trial Also known as Off-Site 37
Slide 38-

Related terms: IND Safety Reports(Investigational New Drug): A report issued by the sponsor of an investigational product when a safety issue arises Submitted to the FDA, investigators and IRBs Required by regulations 21CFR 312.32 (c)(1) *PI and IRB must review these reports 38
Slide 39-

39
Slide 40-

Related terms: DSMB or DSMC: Data Safety Monitoring Board/Committee An independent committee of clinicians, statisticians, ethicists, and other specialists who assess the progress of a trial, its safety and/or its efficacy at specified intervals The committee can make recommendations that a study be continued, modified, or stopped based on the data reviewed (Lui) 40
Slide 41-

Related terms: Unanticipated Problems (UAPs) involving risks to subjects or others: Must meet all of the following criteria: 1. unexpected (in terms of nature, severity, or frequency) given (a) the research procedures that are described in the protocol and informed consent document; and (b) the characteristics of the subject population being studied; 2. related or possibly related to participation in the research 3. suggests that the research places subjects or others at greater risk of harm (including physical, psychological, economic, or social harm) than was previously known or recognized http://www.hhs.gov/ohrp/policy/advevntguid.html 41
Slide 42-

Unanticipated Problems: http://www.hhs.gov/ohrp/policy/advevntguid.html#AA 42
Slide 43-

Examples of UAPs involving risks to subjects or others: include but are not limited to: An interim analysis (DSMB) suggesting additional risk A report (journal article or abstract, etc.) that reveals a change in risks/benefits A breach of confidentiality Change in FDA labeling or withdrawal from marketing of a drug, device, or biological used in a research protocol Incarceration of a subject in a protocol not approved to enroll prisoners Sponsor imposed suspension for risk Protocol violation that may harm subjects or increase risk of harm 43
Slide 44-

Helpful Hints for Reporting UAPs to OHR at TJU Reported via eazUP Electronic Reporting System Unanticipated Problems(OHR-20) paper form still exists on OHR website; Forms If the event poses increased risk, should be reported within 10 working days of learning of the event 44
Slide 45-

Unanticipated Problems: AEs that are serious and UAPs are considered the most important subset of adverse events suggests that the research places subjects or others at a greater risk of harm warrants consideration of substantive changes in the research protocol or informed consent or other corrective actions in order to protect the safety, welfare, or rights of subjects **IRBs have authority to suspend or terminate approval of research that has been associated with unexpected serious harm to subjects (45 CFR 46.113) 45
Slide 46-

Really? Is she ever going to stop talking?
Slide 47-

Learning Objectives: Protocol Violations/Deviations Understand current definitions of protocol deviation versus protocol violation Describe documentation and reporting of protocol deviations 47
Slide 48-

Protocol Violations/Deviations: Definition An unplanned or unintentional departure from an IRB approved protocol, without prior sponsor or IRB approval. NIH IRB Professional Administrators Committee Regulatory Process Workgroup *There is currently no consensus (or definition in CFR or ICH) on how to differentiate between deviation versus violation! 48
Slide 49-

Protocol Violations/Deviations: Protocol Violation is a deviation from the IRB approved protocol that may: Reduce the completeness, accuracy and reliability of study data Contradict or invalidate the Informed Consent Impact the subject’s safety, rights or well-being NIH IRB Professional Administrators Committee Regulatory Process Workgroup 49
Slide 50-

Protocol Violations/Deviations: Protocol Deviation: Has no significant consequence to the subject or protocol integrity and is considered minor A frequently accepted delineation is that a deviation does not expose the subject to increased risk, whereas a violation does Often deviation/violation is considered a joint term, with the only difference being reporting guidelines after the event has been assessed 50
Slide 51-

Protocol Violations/Deviations: May result from the actions of: Subject Investigator Study Staff 51
Slide 52-

Protocol Violations/Deviations: May be unavoidable or unintentional May be purposeful If so, explore the possibility of a waiver, in advance Prospective Protocol Waiver: “Any prospective request for an intentional deviation from the IRB approved protocol except when necessary to eliminate an apparent immediate hazard to a participant” Quorum Review IRB 52
Slide 53-

Examples of Protocol Deviations: Subject follow-up visit occurs out of window (provided this does not affect subject well-being or integrity of study data) Schedule of events is not followed Questionnaire administered out of order Number of subject enrolled exceeds the IRB approved number 53
Slide 54-

Examples of Protocol Violations: Significant risk of harm to the research subject Subject received the wrong treatment or incorrect dose Subject met withdrawal criteria during the study but was not withdrawn Subject received an excluded concomitant medication NIH IRB Professional Administrators Committee Regulatory Process Workgroup 54
Slide 55-

Examples of Protocol Violations: Compromise to the scientific integrity of the data collected Subject was enrolled but does not meet the protocol's eligibility criteria Changing the protocol without prior IRB approval Inadvertent loss of samples or data NIH IRB Professional Administrators Committee Regulatory Process Workgroup 55
Slide 56-

Examples of Protocol Violations: Breach of human subject protection regulations, policies, or procedures on the part of the investigator(s) Failure to obtain informed consent prior to initiation of study-related procedures Inadequate or improper informed consent procedure Falsifying research or medical records NIH IRB Professional Administrators Committee Regulatory Process Workgroup 56
Slide 57-

Examples of Protocol Violations: Noncompliance with federal, state, local or institutional human subject protection regulations, policies, or procedures Working under an expired professional license or certification Performing tests or procedures beyond the individual's professional scope or privilege status (credentialing) Repeated minor deviations A breach of confidentiality NIH IRB Professional Administrators Committee Regulatory Process Workgroup 57
Slide 58-

Reporting Violations/Deviations: The investigator shall also assure that he or she will promptly report to the IRB all changes in the research activity and all unanticipated problems involving risk to human subjects or others, and that he or she will not make any changes in the research without IRB approval, except where necessary to eliminate apparent immediate hazards to human subjects 21CFR312.66 **reporting requirements are defined by individual IRBs and sponsors. 58
Slide 59-

Reporting Violations/Deviations: In general: Deviations: Keep a log The Investigator should review and sign in real time Submit to the IRB with the annual review The sponsor will review during routine monitoring visit Violations: Need to be reported to the IRB and sponsor as they occur Aka: Unanticipated Problem posing risk to subject or others (UAP) 59
Slide 60-

Reporting Violations/Deviations at TJU: 60 Protocol deviations/violations not posing risks to subjects or others are not considered unanticipated problems involving risk and should not be reported to the IRB at the time they occur. It is recommended that you keep a log of protocol deviations/violations in the study file for inclusion in the continuing review submission or final report. Policy GA 120: Reporting and Reviewing Unanticipated Problems Involving Risks to Subjects or Others
Slide 61-

Reporting Violations/Deviations to Quorum: 61
Slide 62-

Lui, M.B. and Davis, K (2013). A Clinical Trials Manual from the Duke Clinical Research Institute. Lessons from a Horse Named Jim, Second Edition. Hoboken, NJ: Wiley-Blackwell. Goldfarb, N (July 2012). Adverse Event Terminology. Journal of Clinical Research Best Practices, 8 (7), 1-17. Goldfarb, N (Nov. 2005). Bringing Method to the madness: Protocol Deviation & Violation Codes. Journal of Clinical Research Best Practices, 1 (11), 1-5. NIH IRB Professional Administrators Committee Regulatory Process Workgroup (11/18/2005), Protocol Deviations and Violations, Version 5.1, 1-2. References: The Code of Federal Regulations, Title 21-Food and Drugs and Title 45, Part 46 Protection of Human Subjects. International Conference on Harmonisation Guidance for Industry, E6 Good Clinical Practice: Consolidated Guidance.
Slide 63-

63